Connect with us
  • Elysium


Daily News Roundup: Monday, 1 July



Welcome to your daily round-up of everything happening in the world of neurorehabilitation.

Research news

Visualising core pathologies of Parkinson’s disease and related disorders in live patients

Like Alzheimer’s disease, a hallmark symptom in PD and DLB is the abnormal accumulation of certain protein structures. In PD and DLB, these aggregates are known as α-synuclein fibrils, which spread throughout the brain and cause damage to neural pathways. Many scientists are trying to develop chemical agents that can selectively bind to α-synuclein and make it detectable via techniques such as positron emission tomography. While a few studies have seen some success with this approach, there are still no PET tracers for α-synuclein that can be used in clinical practice to diagnose PD and DLB in living patients. This is mostly because α-synuclein deposits are small and not overly abundant. Now, in a new study published in the journal Neuron, a team of scientists from Japan has designed a potentially game-changing positron emission tomography tracer for α-synuclein.

Pilot study shows promise for remote cognitive rehabilitation for multiple sclerosis

A pilot study shows promise for a new treatment option for individuals with memory impairments caused by multiple sclerosis. The proof-of-concept study, conducted in ten participants with MS-related memory impairments, assessed the feasibility and impact of six online sessions of TELE-Self-GEN delivered via Zoom. TELE-Self-GEN integrates memory strategies within a metacognitive framework to aid individuals in managing their cognitive challenges.

Novel peptide formulation shows promise of restoring cognitive decline in schizophrenia

chizophrenia is a complicated mental health disorder accompanied by wide range of symptoms such as hallucinations, impaired cognitive ability, and disorganized speech or behavior. It has been associated with anomalies in neurotransmission due to the imbalance of chemical neurotransmitters. Current treatment strategies against schizophrenia involve the administration of antipsychotic drugs, which can cause adverse effects and are associated with a high risk of cardiovascular disease. Moreover, in patients, response to therapeutic drugs is often inadequate as the blood-brain barrier (BBB), a protective barrier of cells, strictly regulates the movement of ions and molecules into the brain.

To overcome the hurdle of BBB and facilitate the transport of therapeutic drugs into brain tissue to treat schizophrenia, researchers from the from Japan Advanced Institute of Science and Technology (JAIST), have explored the applicability of receptor-mediated transcytosis (RMT) using low-density lipoprotein receptor-related protein 1.

Company and financial neuro-rehab news

ASPIRE-FTD Phase 1/2 Clinical Trial

AviadoBio, a gene therapy company dedicated to developing and delivering potentially transformative medicines for neurodegenerative disorders, has announced that its Phase 1/2 ASPIRE-FTD clinical trial is now open and recruiting patients in the United States at The Ohio State University. ASPIRE-FTD is evaluating AviadoBio’s investigational gene therapy, AVB-101, in people with frontotemporal dementia (FTD) with progranulin (GRN) gene mutations (FTD-GRN). The study is also recruiting in Europe with study sites in the Netherlands, Poland, and Spain, with additional sites expected to open in multiple countries.

Neurotechnology news

CraniUS awarded $1 million grant

CraniUS, an R&D company focused on groundbreaking diagnostics and treatments for patients with chronic brain disease, has been awarded a competitive $1 million grant from the State of Maryland as part of Governor Wes Moore’s Build Our Future Innovation Infrastructure Pilot Program. Funds will be used to advance CraniUS’s transformative, skull-embedded technology designed to transform brain disease treatment by bypassing the blood-brain barrier.